News - Tecfidera, Aubagio

Filter

Current filters:

TecfideraAubagio

Popular Filters

Mixed US views on Gilenya, Aubagio and Tecfidera as breakthrough MS drugs

03-09-2013

More than half of surveyed neurologists consider US biotech firm Biogen Idec's (Nasdaq: BIIB) Tecfidera…

AubagioBiogen IdecGilenyaMarkets & MarketingNeurologicalNorth AmericaNovartisPharmaceuticalPricingSanofiTecfidera

Multiple sclerosis market could reach $18.3 billion in 2018

19-08-2013

The multiple sclerosis (MS) market is expected to peak at $18.3 billion in 2018, according to healthcare…

AubagioBiogen IdecFinancialGilenyaGlobalNovartisPharmaceuticalSanofiTecfidera

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top